What ARIZ Precision Medicine does

ARIZ Precision Medicine is a privately held, pre-clinical stage biopharmaceutical company founded in 2016 (per corporate history) and headquartered in Davis, California. The company develops precision ligand-targeted siRNA cancer therapies designed to destroy cancer driver proteins while sparing healthy cells. Its therapeutic strategy targets PRDM (Positive Regulatory Domain-containing Methyltransferases) genes and proteins, which the company characterizes as master regulators of gene expression that control cell differentiation and proliferation. ARIZ serves the oncology market across multiple indications, including lung, breast, colon, multiple myeloma, leukemia, prostate, liver, and lymphoma.

ARIZ's core technology is the PRDM Oncogene Targeting Platform, which combines siRNA compounds with targeting peptides and PEG-protected nanoparticle drug delivery systems to concentrate drug payloads inside cancer cells while leaving normal cells largely undamaged. Pre-clinical data shows the lead candidate, ARIZ-047, can eliminate over 90% of lung cancer cells (A549) in cell culture with a single low dose while affecting only 5-10% of normal cells, with efficacy also demonstrated in animal models. The platform is protected by a broad IP portfolio including issued US Patent 12,012,597 B2 covering pharmaceutical compositions and methods for treating cancer using siRNA to modulate PRDM2/RIZ protein, plus licensed PRDM gene/protein patents and additional provisional composition-of-matter patents.

ARIZ operates an asset-light, partnership-driven business model with no current product revenue. Monetization is planned through licensing deals, milestone payments, and royalty streams generated via strategic partnerships with large pharmaceutical companies for clinical development and commercialization. As of late 2024, ARIZ has raised approximately $2.61 million in cumulative funding across seed and angel rounds, with named investors including Moneta Ventures and Sacramento Angels, plus 13 angel investors at AngelCon. The company builds visibility and partnership pipeline through industry channels including BIO International Convention, the J.P. Morgan Healthcare Conference (J&J Innovation Quick Pitch, 2020), and the CLSI FAST Advisory Program, and has earned recognition including the BUZZ of BIO award (2020) and Golden Tickets to Bakar Labs (2024).

Name

ARIZ Precision Medicine

Legal name

ARIZ Precision Medicine, Inc.

Website

https://arizbio.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

ARIZ Precision Medicine is a pre-clinical biopharmaceutical company developing precision siRNA cancer therapies that target PRDM oncogenes via nanoparticle drug delivery, with lead candidate ARIZ-047 aimed at lung cancer and a pipeline spanning multiple oncology indications.

Ownership category

akta.pro rank

Product category

Precision Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

siRNA Therapeutics (gene silencing) (HLAAADAB)

akta.pro secondary industries

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG), Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK), Translational Medicine & Biomarkers (HLAIALAF), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Precision cancer medicine
• SiRNA oncology therapeutics
• Nanoparticle drug delivery
• Nucleic acid therapy
• Preclinical biopharmaceutical development

Headquarters

HQ city

Davis

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Drug Development and Licensing: Pre-clinical biopharmaceutical company developing precision ligand targeted siRNA cancer therapies. Revenue model is expected to come from pharmaceutical partnerships, licensing deals, and eventual product commercialization upon FDA approval. Currently in pre-clinical stage with no revenue.
2. Strategic Partnerships: The company seeks to partner with pharmaceutical companies to advance products through clinical development and commercialization, generating partnership fees, milestone payments, and royalty streams.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

ARIZ Precision Medicine is a preclinical-stage biopharmaceutical company developing precision ligand-targeted siRNA (small interfering RNA) cancer therapies. Its lead drug candidate, ARIZ-047, uses siRNA combined with nanoparticle drug delivery systems to target and modulate PRDM (Positive Regulatory Domain-containing Methyltransferases) oncogenes, with demonstrated efficacy in killing lung cancer cells in cell culture and animal models. The company is pursuing strategic partnerships with pharmaceutical companies for clinical development and eventual commercialization.

Product overview

ARIZ Precision Medicine is a preclinical stage biopharmaceutical company developing precision ligand targeted siRNA cancer therapies. The company's core offering is the PRDM Oncogene Targeting Platform™, which uses siRNA technology combined with nanotechnology-based drug delivery systems to modulate PRDM genes and proteins. Lead drug candidate ARIZ-047 targets lung cancer cells. The platform addresses multiple cancer types including lung, breast, colon, myeloma, leukemia, prostate, liver, and lymphoma through different PRDM targets (PRDM 2, 14, 1, 16).

Differentiator

Problem solved

Functional benefit

Products and services

• ARIZ-047 A highly specific siRNA drug candidate using precision ligand targeted siRNA therapy for cancer treatment, demonstrated effective in killing lung cancer cells in both cell culture and animal model experiments. Targets PRDM2/RIZ protein expression and covers a broad range of cancers under US Patent 12,012,597 B2.
• PRDM-targeted siRNA Cancer Therapies A pipeline of small interfering RNA (siRNA) compounds designed to target and destroy cancer cell driver proteins via PRDM gene modulation, combined with targeting peptides and nanoparticle drug delivery systems. Addresses multiple cancer types including lung, breast, colon, myeloma, leukemia, prostate, liver, and lymphoma through different PRDM targets (PRDM 2, 14, 1, 16).

Quantifiable outcome

• Kills >90% of cancer cells in cell culture with single low dose while only affecting 5-10% of normal cells
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• NATA (Nucleic Acid Therapy Accelerator)coreStrategic or Co-development Partner · 21 November 2024Collaboration between ARIZ and MRC's Nucleic Acid Therapy Accelerator to harness their combined platforms to develop nucleic acid therapy drug candidates for novel gene targets with strong genetic associations to leading cancers. Combines NATA's expertise in NAT design with ARIZ's RNAi compounds for treating a range of cancers.
• Bakar LabscoreStrategic or Co-development Partner · 11 July 2024ARIZ won Golden Tickets to Bakar Labs sponsored by BrightEdge/American Cancer Society. This provides access to laboratory space and resources for biotech development.
• UC Davis (UCD Venture Catalyst DRIVE program)coreStrategic or Co-development Partner · 14 January 2020ARIZ is affiliated with University of California, Davis as a participant in the UCD Venture Catalyst DRIVE program. Located at UC Davis-HM Clause Life Science Innovation Center for access to research infrastructure and talent.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Alnylam Pharmaceuticals: Alnylam is the leading siRNA therapeutics company with a broad clinical pipeline across multiple therapeutic areas including oncology. It is comparable to ARIZ as the reference siRNA platform against which ARIZ's narrower, cancer-focused siRNA approach is benchmarked.
• Dicerna Pharmaceuticals (Novo Nordisk): Dicerna was a clinical-stage siRNA company acquired by Novo Nordisk. It is comparable as a precedent for how a siRNA platform developer can be acquired, providing a relevant valuation and strategic-exit benchmark for ARIZ.

Direct peers

• Arrowhead Pharmaceuticals: Arrowhead develops RNAi-based therapeutics with a significant oncology pipeline using proprietary siRNA delivery platforms (TRiM and others). It is the closest direct peer to ARIZ in applying siRNA to oncology targets and competing for pharma partnership attention.
• Sirnaomics: Sirnaomics develops siRNA-based therapeutics with both oncology and anti-fibrotic programs using its PNP (polypeptide nanoparticle) delivery system. It is a direct peer in modality (siRNA + nanoparticle) and target space (cancer).

Emerging players

• Phio Pharmaceuticals: Phio is developing RNAi-based therapeutics for cancer and other indications using its self-delivering RNAi platform. Comparable to ARIZ as a smaller, cancer-focused siRNA peer competing for similar partnership and investment capital.
• Arcturus Therapeutics: Arcturus develops RNA-based therapeutics including siRNA and mRNA candidates, with oncology and rare disease programs. It is comparable as another RNA-medicine platform with adjacent delivery technology and oncology ambitions.
• MiNA Therapeutics: MiNA develops RNA-based therapeutics, primarily saRNA (small activating RNA), for cancer and other diseases. Comparable as a precision RNA oncology platform with a similar size, stage, and partnership-driven business model.
• Praxis Precision Medicines: Praxis is a clinical-stage precision medicine company targeting CNS disorders with genetically defined patient populations. Comparable as a similarly sized precision-medicine platform that licenses or partners early-stage assets in tightly defined indications.
• Silenseed: Silenseed is developing siRNA-based therapeutics delivered via its siGLOBE platform, with oncology applications. Comparable as a small, cancer-focused siRNA platform targeting solid tumors.

Others

• Genevant Sciences: Genevant is a lipid nanoparticle (LNP) delivery technology company spun out of Arbutus, enabling RNA therapeutics including siRNA. Comparable as an enabling technology player whose delivery IP overlaps with ARIZ's nanoparticle delivery approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/arizbio

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ARIZ Precision Medicine